AGCJ
ARIA

Alden Global Capital (Jersey)’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Alden Global Capital (Jersey)’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,055,900
Closed -$7.2M – 30
2013
Q4 		$7.2M Buy
+1,055,900
New +$5.7M 1.82% 17

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Alden Global Capital (Jersey)'s ARIA Position: Q1 2014 in Review

Alden Global Capital (Jersey) sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2014, closing a stake of 1,055,900 shares — an estimated $7.2M sold.

Alden Global Capital (Jersey) first reported a position in ARIA in Q4 2013 and held it in 1 quarter. The position peaked at $7.2M in Q4 2013. 171 funds tracked by Wall St. Rank hold ARIA as of Q1 2014.

  • Alden Global Capital (Jersey) reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Alden Global Capital (Jersey) sold 1,055,900 Ariad Pharmaceuticals Inc shares in Q1 2014, an estimated $7.2M.
  • Alden Global Capital (Jersey) first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • Alden Global Capital (Jersey)'s Ariad Pharmaceuticals Inc position peaked at $7.2M in Q4 2013.
  • 171 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2014.

Based on Alden Global Capital (Jersey)'s 13F filing for Q1 2014, filed 15 May 2014.